Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer.

JCO precision oncology - 1 Jul 2022

Thein Kyaw Z, Biter Amadeo B, Banks Kimberly C, Duda Andrew W, Saam Jennifer, Roszik Jason, Janku Filip, Skoulidis Ferdinandos, Heymach John V, Kopetz Scott, Meric-Bernstam Funda, Hong David S

Abstract excerpt

PURPOSE: KRAS is the most mutated proto-oncogene that has been identified in cancer, and treatment of patients with KRAS mutations remains an arduous challenge. Recently, KRASG12C mutation has attracted special interest because it is now considered potentially druggable with recently developed covalent small-molecule KRASG12C inhibitors. Nevertheless, to date, there have been no large-scale analyses of liquid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Pancreatic Ductal

Share to Circulating Tumor DNA

Share to Colorectal Neoplasms

Share to Neoplasms, Unknown Primary

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 35862868
DOI: 10.1200/PO.21.00547
PMCID: PMC9365336

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer.PMID 35862868Read ↗

KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.Semantic proximity Read ↗

Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib.Semantic proximity Read ↗

Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practiceSemantic proximity Read ↗

Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.Semantic proximity Read ↗

KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patientsSemantic proximity Read ↗

Landscape of KRAS G12C , Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS -Mutated CancersSemantic proximity Read ↗

The dynamic evolution of circulating tumor cells during glecirasib treatment predicts survival and resistance in gastrointestinal tumors with KRASG12C mutation.Semantic proximity Read ↗

KRAS Mutations in Cholangiocarcinoma: Prevalence, Prognostic Value, and KRAS G12/G13 Detection in Cell-Free DNA.Semantic proximity Read ↗

Development of a prediction system for KRAS mutation detection via circulating tumour DNA analysis among patients with unresectable pancreatic cancerSemantic proximity Read ↗

KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal settingSemantic proximity Read ↗

Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancerSemantic proximity Read ↗

Distribution of KRAS G12C Somatic Mutations across Race, Sex, and Cancer TypeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.